Mortality in Patients after a Recent Myocardial Infarction: A Randomized, Placebo-Controlled Trial of Azimilide Using Heart Rate Variability for Risk Stratification

A. John Camm, Craig M. Pratt, Peter J. Schwartz, Hussein R. Al-Khalidi, Maria J. Spyt, Michael J. Holroyde, Roger Karam, Edmund H. Sonnenblick, Jose M G Brum

Research output: Contribution to journalArticlepeer-review

Abstract

Background - Depressed left ventricular function (LVF) and low heart rate variability (HRV) identify patients at risk of increased mortality after myocardial infarction (MI). Azimilide, a novel class III antiarrhythmic drug, was investigated for its effects on mortality in patients with depressed LVF after recent MI and in a subpopulation of patients with low HRV. Methods and Results - A total of 3717 post-MI patients with depressed LVF were enrolled in this randomized, placebo-controlled, double-blind study of azimilide 100 mg on all-cause mortality. Placebo patients with low HRV had a significantly higher 1-year mortality than those with high HRV (>20 U; 15% versus 9.5%, P

Original languageEnglish
Pages (from-to)990-996
Number of pages7
JournalCirculation
Volume109
Issue number8
DOIs
Publication statusPublished - Mar 2 2004

Keywords

  • Antiarrhythmia agents
  • Azimilide
  • Heart rate
  • Trials

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Mortality in Patients after a Recent Myocardial Infarction: A Randomized, Placebo-Controlled Trial of Azimilide Using Heart Rate Variability for Risk Stratification'. Together they form a unique fingerprint.

Cite this